Press Releases

Year None202320222021202020192018

September 18, 2023

Black Diamond Therapeutics Announces CEO Transition

September 11, 2023

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

September 05, 2023

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

August 11, 2023

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

June 29, 2023

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

June 28, 2023

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

June 27, 2023

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

June 13, 2023

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

June 02, 2023

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

May 09, 2023

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Displaying 1 - 10 of 15